GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Renovaro Inc (NAS:RENB) » Definitions » EV-to-FCF

Renovaro (Renovaro) EV-to-FCF : -20.18 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Renovaro EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Renovaro's Enterprise Value is $231.99 Mil. Renovaro's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.49 Mil. Therefore, Renovaro's EV-to-FCF for today is -20.18.

The historical rank and industry rank for Renovaro's EV-to-FCF or its related term are showing as below:

RENB' s EV-to-FCF Range Over the Past 10 Years
Min: -76.65   Med: -24.71   Max: -3.56
Current: -20.37

During the past 12 years, the highest EV-to-FCF of Renovaro was -3.56. The lowest was -76.65. And the median was -24.71.

RENB's EV-to-FCF is ranked worse than
100% of 393 companies
in the Biotechnology industry
Industry Median: 4.47 vs RENB: -20.37

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-01), Renovaro's stock price is $1.485. Renovaro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.700. Therefore, Renovaro's PE Ratio for today is At Loss.


Renovaro EV-to-FCF Historical Data

The historical data trend for Renovaro's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Renovaro EV-to-FCF Chart

Renovaro Annual Data
Trend Mar13 Dec14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.76 -18.29 -11.92 -6.36 -3.37

Renovaro Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.01 -4.55 -3.37 -25.02 -19.16

Competitive Comparison of Renovaro's EV-to-FCF

For the Biotechnology subindustry, Renovaro's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Renovaro's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Renovaro's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Renovaro's EV-to-FCF falls into.



Renovaro EV-to-FCF Calculation

Renovaro's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=231.989/-11.494
=-20.18

Renovaro's current Enterprise Value is $231.99 Mil.
Renovaro's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Renovaro  (NAS:RENB) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Renovaro's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.485/-0.700
=At Loss

Renovaro's share price for today is $1.485.
Renovaro's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.700.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Renovaro EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Renovaro's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Renovaro (Renovaro) Business Description

Traded in Other Exchanges
Address
2080 Century Park East, Suite 906, Los Angeles, CA, USA, 90067
Renovaro Biosciences Inc Formerly Enochian BioSciences Inc is a biopharmaceutical company. It is engaged in the research and development of pharmaceutical and biological products for the treatment of HIV, HBV, and cancer with the intent to manufacture said products.
Executives
Leni Boeren director 2080 CENTURY PARK EAST, #906, LOS ANGELES CA 90067
Ruud Hendriks director CHATEAU D'AZUR, BLVD D'LTALIE 44, MONACO O9 C11298000
Ole Abildgaard 10 percent owner VEDBAEK STRANDVEJ 506, VEDBAEK G7 2950
Francois Binette officer: Executive Vice President 2022 N. ALVARADO STREET, LOS ANGELES CA 90039
Serhat Gumrukcu 10 percent owner 2080 CENTURY CITY EAST, SUITE 906, LOS ANGELES CA 90067
Rene Sindlev director, 10 percent owner FRUEBJERGVEJ 3 BOX 62, COPENHAGEN G7 2100
Carl Forest Sandler other: Former director see note below 330 EAST 33RD STREET, APARTMENT 3A, NEW YORK FL 10016
Jayne Mcnicol director 606 NORTHERN AVENUE, MILL VALLEY CA 94941
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Carol L Brosgart director C/O TOBIRA THERAPEUTICS, INC., 701 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Henrik Gronfeldt-sorensen director STUMPEDYSSEVEJ 17, HORSHOLM G7 2970
Luisa Puche officer: Chief Financial Officer 318 NE 104TH STREET, MIAMI FL 33138
Luc Debruyne director NOORDENWINDHELLING 2 02/05, OOSTDUINKERKE C9 8670
Anderson Wittekind William 10 percent owner 8581 SANTA MONICA BLVD, LOS ANGELES CA 90069
Leire, Eric Jean Marie director, officer: CEO; President C/O DANDRIT BIOTECH USA, INC., P.O. BOX 189, RANDOLPH VT 05060

Renovaro (Renovaro) Headlines

From GuruFocus